Fresnillo (LSE: FRES): Can the world’s largest silver miner hold its record gains as 2026 output dips?
TCS CEO corrects three major Nashik facts: Nida Khan was not HR head, unit not shut, no POSH complaints on record
Read More Pharma Industry News Gilead’s CAR T breakthrough: Yescarta delivers consistent results beyond transplant settings Yescarta shows durable survival and response benefits in second-line large B-cell lymphoma across transplant-eligible and ineligible patients. Read the latest trial update. byPallavi MadhirajuDecember 8, 2025